[go: up one dir, main page]

MX337850B - Lipoatrofia cosmetica medicinal. - Google Patents

Lipoatrofia cosmetica medicinal.

Info

Publication number
MX337850B
MX337850B MX2011009212A MX2011009212A MX337850B MX 337850 B MX337850 B MX 337850B MX 2011009212 A MX2011009212 A MX 2011009212A MX 2011009212 A MX2011009212 A MX 2011009212A MX 337850 B MX337850 B MX 337850B
Authority
MX
Mexico
Prior art keywords
lipoatrophy
corticosteroids
medicinal cosmetic
cosmetic lipoatrophy
injections
Prior art date
Application number
MX2011009212A
Other languages
English (en)
Other versions
MX2011009212A (es
Inventor
Doris Hexsel
Original Assignee
Doris Hexsel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Doris Hexsel filed Critical Doris Hexsel
Publication of MX2011009212A publication Critical patent/MX2011009212A/es
Publication of MX337850B publication Critical patent/MX337850B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

Las inyecciones locales de corticoesteroides, más específicamente, las inyecciones intralesionales de corticoesteroides y, de preferencia, de triamcinolona y sus derivados, son adecuadas para producir medicamentos que se van a inyectar en la grasa subcutánea a niveles profundos, para provocar lipoatrofia cosmética de los pequeños depósitos de grasa en la cara y el cuerpo.
MX2011009212A 2009-03-02 2010-03-02 Lipoatrofia cosmetica medicinal. MX337850B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20906509P 2009-03-02 2009-03-02
PCT/BR2010/000059 WO2010099587A1 (en) 2009-03-02 2010-03-02 Medicinal cosmetic lipoatrophy

Publications (2)

Publication Number Publication Date
MX2011009212A MX2011009212A (es) 2011-12-06
MX337850B true MX337850B (es) 2016-03-23

Family

ID=42709157

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009212A MX337850B (es) 2009-03-02 2010-03-02 Lipoatrofia cosmetica medicinal.

Country Status (11)

Country Link
US (2) US9220717B2 (es)
EP (1) EP2403502A4 (es)
JP (1) JP6006940B2 (es)
KR (1) KR20120104487A (es)
CN (1) CN102341109A (es)
AU (1) AU2010220830B2 (es)
BR (1) BRPI1007812B1 (es)
CA (1) CA2754008C (es)
MX (1) MX337850B (es)
RU (1) RU2530629C2 (es)
WO (1) WO2010099587A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014001066A2 (pt) * 2011-07-20 2017-02-21 Allergan Inc toxinas botulínicas para uso em um método para tratamento de depósitos adiposos
US11241412B2 (en) 2015-10-12 2022-02-08 Hk Pharma Tumescent infiltration drug delivery of cannabinoids
US10493024B2 (en) * 2015-10-12 2019-12-03 Hk Tumescent Pharma Corporation Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity
KR101972588B1 (ko) * 2018-07-31 2019-04-26 정채홍 지방분해 및 지방제거 시술 전처리용 조성물
US10835502B2 (en) 2018-10-16 2020-11-17 Polithera, Inc. Alcohol-based compositions and uses thereof
EP3917507A4 (en) * 2019-01-31 2022-11-09 HK Pharma ADMINISTRATION OF CANNABINOIDS BY TUMESCENT INFILTRATION

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
US20050143347A1 (en) * 2003-12-22 2005-06-30 Aventis Pharma Deutschland Gmbh Medicinal lipolysis of accumulations of fat
DE10361067A1 (de) * 2003-12-22 2005-07-14 Aventis Pharma Deutschland Gmbh Medikamentöse Lipolyse von Fettansammlungen
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
ATE521355T1 (de) * 2004-05-19 2011-09-15 Los Angeles Biomed Res Inst Verwendung eines detergens zur nicht- chirurgischen entfernung von fett
RU2401098C2 (ru) * 2004-12-14 2010-10-10 Менарини Ричерке С.П.А. Фармацевтические композиции для лечения целлюлита
US20060211665A1 (en) * 2005-03-17 2006-09-21 Ranawat Chitranjan S Reduction of postoperative pain medication
EP1888101B1 (en) * 2005-06-06 2012-03-21 Georgetown University Compositions and methods for lipo modeling

Also Published As

Publication number Publication date
BRPI1007812A2 (pt) 2016-02-23
AU2010220830A1 (en) 2011-10-13
MX2011009212A (es) 2011-12-06
US9408857B2 (en) 2016-08-09
BRPI1007812B1 (pt) 2017-09-26
US20130116223A1 (en) 2013-05-09
EP2403502A1 (en) 2012-01-11
CN102341109A (zh) 2012-02-01
KR20120104487A (ko) 2012-09-21
EP2403502A4 (en) 2012-11-07
US20140213562A1 (en) 2014-07-31
RU2011139015A (ru) 2013-04-10
CA2754008A1 (en) 2010-09-10
RU2530629C2 (ru) 2014-10-10
CA2754008C (en) 2016-04-26
JP6006940B2 (ja) 2016-10-12
WO2010099587A1 (en) 2010-09-10
JP2012519189A (ja) 2012-08-23
AU2010220830B2 (en) 2016-07-14
US9220717B2 (en) 2015-12-29

Similar Documents

Publication Publication Date Title
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
WO2009093104A3 (en) Use of transesterified olive oil in the cosmetic field
CA2863568A1 (en) Topical use of a skin-commensal prebiotic agent and compositions containing the same
MX2011007536A (es) Compuestos beta amino ester y usos de los mismos.
MX355080B (es) Mejora de la apariencia de la piel con aumento en la intensidad cromatica de la piel.
MY165086A (en) Formulations of rifaximin and uses thereof
MX337850B (es) Lipoatrofia cosmetica medicinal.
MY173215A (en) Acetylcysteine compositions and methods of use thereof
MX2012007256A (es) Composicioes estimuladoras de paxilina y usos comesticos de las mismas.
HU0800434D0 (en) Template to determine the places of the injections, especially for regular medicament injection and/or blood testing
MX347848B (es) Uso cosmético de las sulfoniloxibencilaminas n-sustituidas y compuestos relacionados.
MX2018004616A (es) Cosmetica qie tiene bacterias probioticas.
WO2010104301A3 (en) Cosmetic composition for skin moisturizing
WO2012012497A3 (en) Non-tacky, film-forming water-in-oil cosmetic emulsion
PH12014502314B1 (en) Optimised subcutaneous therapeutic agents
SG10201906172XA (en) Regulation of glucose metabolism using anti-cgrp antibodies
CL2012002781A1 (es) Producto que comprende un cuerpo de alimento compuesto por un componente de alimento y un componente de infusion que contiene mal todextrina en una concentracon de 5 a 65% con respecto al cuerpo del alimento; producto alimenticio; metodo para producir un cuerpo de alimento infusionado; y formulaciones de infusion.
WO2011113785A3 (en) A cosmetic composition for rejuvenating skin appearance
EP4233536A3 (en) Method for enhancing tumor growth
WO2015063613A3 (en) Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
UA105940C2 (uk) Лікарська комбінація з теоброміном та опіатом і її використання в лікуванні кашлю
WO2014023649A3 (en) Dermal cosmetic compositions having osmoprotecting activity
PL2066409T3 (pl) Zastosowanie ekstraktu z quinoa jako kosmetycznego i farmaceutycznego środka czynnego odchudzającego i/lub jako środka czynnego zapobiegającego tworzeniu się nowych tłuszczów w ludzkim ciele
WO2009147345A3 (fr) Association d'extraits de passiflore et d'anchuse utilisable en cosmetique
ATE519479T1 (de) Kosmetikum mit anti-alterungswirkung

Legal Events

Date Code Title Description
FG Grant or registration